Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Let's Sequence These Guys | Main | Patent Chart Update »

April 8, 2010

ACS Med Chem Letters

Email This Entry

Posted by Derek

Since I'm on the editorial board, I should point out that the first full issue of ACS Medicinal Chemistry Letters is up, with free access for the occasion. I note with approval Dennis Liotta's lead-off editorial, which mentions that the journal will be introducing a section to highlight key patents - as far as I can tell, this is the first time a med-chem journal has explicitly acknowledged that this is where the real cutting-edge stuff often first appears in the field. (And no, I didn't have anything to do with the current batch of papers, in case anyone's wondering).

Comments (15) + TrackBacks (0) | Category: The Scientific Literature


COMMENTS

1. Anonymous on April 8, 2010 12:37 PM writes...

Why does the journal have only a new paper or two per week? Is that because submissions are low with the new journal? Or does it intend to have a more selective or shorter issue than, say, J Med Chem?

Permalink to Comment

2. milkshake on April 8, 2010 1:19 PM writes...

Organic Process R&D is another ACS journal that reports on patents, in their case it is lot easier because they are concerned mostly with process patents of the method of preparation kind, where the usefulness is relatively easy to figure out from the patent examples. I think it will be harder to separate good stuff from tailings in medchem patents because very often there is no activity data in the composition-of matter medchem patent hence it may be hard to make a comparison with other known series (unless one takes the trouble to resynthesize the compounds)

Permalink to Comment

3. anchor on April 8, 2010 2:10 PM writes...

I am in full agreement with milkshake. When it comes to patents in med.chem, you have all three variations (good, bad and ugly). But, with Derek in the the front seat, am sure that one can anticipate a good direction.
Milkshake: how did your interview go? Goodluck!

Permalink to Comment

4. milkshake on April 8, 2010 2:17 PM writes...

looks like I will have the the job - I was told unofficially by my future bosses. Nothing in writing yet, they are creating a staff position for me - one that was not opened when I interviewed - and its a bit slow administration-wise.

Permalink to Comment

5. Chemjobber on April 8, 2010 2:39 PM writes...

That's the best news I've heard all day, milkshake. Congrats.

Permalink to Comment

6. Hap on April 8, 2010 2:46 PM writes...

Woo-hoo! Congratulations, Milkshake.

Permalink to Comment

7. Wavefunction on April 8, 2010 2:55 PM writes...

Congrats milk!

Permalink to Comment

8. anchor on April 8, 2010 3:21 PM writes...

Milkshake : I just stepped into my lab after posting (my blog) and then came back to see that you have responded. Further, you have job at hand! Wow! Congrats and as #5 says the best news during these unpredictable and troubling times.

Permalink to Comment

9. mitch on April 8, 2010 6:37 PM writes...

You can see the latest articles in all of their graphical abstract splendor from here:

http://www.chemfeeds.com/acsmedchemlett.php

Mitch

Permalink to Comment

10. DC on April 9, 2010 5:20 AM writes...

=Congrats Milkshake, you have truly been a great help to me and to others as well. Thanks for your always prompt and detailed replies to my questions and your wonderful insight.

Permalink to Comment

11. former process chemist on April 9, 2010 7:15 AM writes...

Thanks for the tip on milkshake. He's got a great site too.

Permalink to Comment

12. petros on April 9, 2010 7:37 AM writes...

It will be intersting to see how many hot papers appear in this journal rather than J Med Chem, but I guess initialy we won't see many issues because J Med Chem only had a few (3-5) brief communications each issue. That's not going to generate many issues.

I guess longer term the journal may impact on BMCL as well, and then produce more issues (assuming there's still some med chem going on).


The patent section might be interesting but it will be a minefield trying to select out from the potential NCE filings that appear each week. And what criteria will be employed for the section? New targets? New leads? or ?


Permalink to Comment

13. Nick K on April 9, 2010 12:39 PM writes...

Some very nice, meaty work in the first issue, and better than a lot of the stuff in J. Med. Chem. Let's hope the journal can maintain the standard.

PS: Well done Milkshake!

Permalink to Comment

14. DrSnowboard on April 12, 2010 3:22 AM writes...

Anybody else find 49 authors on a Letter a little OTT?

Permalink to Comment

15. CanChem on April 12, 2010 8:31 AM writes...

@14 - certainly a lot of authors, but not wholly impossible if it's first disclosure of everything from HTS through to clinical selection. I think you're referring to DOI:10.1021/ml900018m, so having two organizations involved certainly helps to bulk out authorship as well.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings